Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 2
1997 1
1998 1
1999 1
2000 4
2001 3
2002 1
2003 2
2004 3
2005 1
2006 6
2007 4
2008 7
2009 11
2010 9
2011 13
2012 15
2013 14
2014 31
2015 36
2016 38
2017 44
2018 52
2019 49
2020 57
2021 82
2022 78
2023 66
2024 44

Text availability

Article attribute

Article type

Publication date

Search Results

589 results

Results by year

Filters applied: . Clear all
Page 1
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Salles G, Wierda WG, Izumi R, Munugalavadla V, Patel P, Wang MH, Wong S, Byrd JC. Sharman JP, et al. Lancet. 2020 Apr 18;395(10232):1278-1291. doi: 10.1016/S0140-6736(20)30262-2. Lancet. 2020. PMID: 32305093 Free PMC article. Clinical Trial.
We compare the efficacy of acalabrutinib with or without obinutuzumab against chlorambucil with obinutuzumab in patients with treatment-naive chronic lymphocytic leukaemia. METHODS: ELEVATE TN is a global, phase 3, multicentre, open-label study in patients with treatment- …
We compare the efficacy of acalabrutinib with or without obinutuzumab against chlorambucil with obinutuzumab in patients with treatment-n …
BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma.
Eyre TA, Shah NN, Dreyling M, Jurczak W, Wang Y, Cheah CY, Song Y, Gandhi M, Chay C, Sharman J, Andorsky DJ, Messersmith HM, Ruppert AS, Muthig VA, Ito R, Wang ML. Eyre TA, et al. Future Oncol. 2022 Nov;18(36):3961-3969. doi: 10.2217/fon-2022-0976. Epub 2022 Nov 15. Future Oncol. 2022. PMID: 36377973
This phase III, head-to-head, randomized study (NCT04662255) will evaluate whether pirtobrutinib is superior to investigator's choice of covalent BTKi in patients with previously treated, BTKi-naive mantle cell lymphoma. MCL is an uncommon type of B-cell non-Hodgkin lympho …
This phase III, head-to-head, randomized study (NCT04662255) will evaluate whether pirtobrutinib is superior to investigator's choice of cov …
Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology.
Rosano GMC, Moura B, Metra M, Böhm M, Bauersachs J, Ben Gal T, Adamopoulos S, Abdelhamid M, Bistola V, Čelutkienė J, Chioncel O, Farmakis D, Ferrari R, Filippatos G, Hill L, Jankowska EA, Jaarsma T, Jhund P, Lainscak M, Lopatin Y, Lund LH, Milicic D, Mullens W, Pinto F, Ponikowski P, Savarese G, Thum T, Volterrani M, Anker SD, Seferovic PM, Coats AJS. Rosano GMC, et al. Eur J Heart Fail. 2021 Jun;23(6):872-881. doi: 10.1002/ejhf.2206. Epub 2021 May 20. Eur J Heart Fail. 2021. PMID: 33932268 Free article.
Also, dynamic changes in estimated glomerular filtration rate may occur during the course of HF, resulting in inappropriate dose reduction or even discontinuation of decongestive or neurohormonal modulating therapy in clinical practice. As patients with HF are rarely naive …
Also, dynamic changes in estimated glomerular filtration rate may occur during the course of HF, resulting in inappropriate dose reduction o …
Maintenance of Human Naive Pluripotent Stem Cells.
Rostovskaya M. Rostovskaya M. Methods Mol Biol. 2022;2416:73-90. doi: 10.1007/978-1-0716-1908-7_6. Methods Mol Biol. 2022. PMID: 34870831
Naive pluripotent stem cells are the in vitro counterparts of pre-implantation embryonic epiblast. ...As such, choosing the most appropriate method for naive hPSC maintenance can pose a significant challenge. This chapter presents an optimized system called PXGL for …
Naive pluripotent stem cells are the in vitro counterparts of pre-implantation embryonic epiblast. ...As such, choosing the most appr …
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, Chiari R, Bearz A, Lin CC, Gadgeel SM, Riely GJ, Tan EH, Seto T, James LP, Clancy JS, Abbattista A, Martini JF, Chen J, Peltz G, Thurm H, Ou SI, Shaw AT. Solomon BJ, et al. Lancet Oncol. 2018 Dec;19(12):1654-1667. doi: 10.1016/S1470-2045(18)30649-1. Epub 2018 Nov 6. Lancet Oncol. 2018. PMID: 30413378 Clinical Trial.
One patient in EXP4 died before receiving lorlatinib and was excluded from the safety analysis set. In treatment-naive patients (EXP1), an objective response was achieved in 27 (90.0%; 95% CI 73.5-97.9) of 30 patients. ...INTERPRETATION: Consistent with its broad ALK mutat …
One patient in EXP4 died before receiving lorlatinib and was excluded from the safety analysis set. In treatment-naive patients (EXP1 …
Capacitation of Human Naive Pluripotent Stem Cells.
Rostovskaya M. Rostovskaya M. Methods Mol Biol. 2022;2416:117-131. doi: 10.1007/978-1-0716-1908-7_9. Methods Mol Biol. 2022. PMID: 34870834
Naive and primed pluripotent stem cells resemble epiblast cells of the pre-implantation and post-implantation embryo, respectively. ...Naive hPSCs after capacitation can be differentiated further to somatic lineages, thus reproducing the order of developmental event …
Naive and primed pluripotent stem cells resemble epiblast cells of the pre-implantation and post-implantation embryo, respectively. . …
Establishment and Maintenance of the Human Naive CD4(+) T-Cell Compartment.
Silva SL, Sousa AE. Silva SL, et al. Front Pediatr. 2016 Oct 31;4:119. doi: 10.3389/fped.2016.00119. eCollection 2016. Front Pediatr. 2016. PMID: 27843891 Free PMC article. Review.
The naive CD4(+) T-cell compartment is considered essential to guarantee immune competence throughout life. Its replenishment with naive cells with broad diverse receptor repertoire, albeit with reduced self-reactivity, is ensured by the thymus. ...
The naive CD4(+) T-cell compartment is considered essential to guarantee immune competence throughout life. Its replenishment with …
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Shaw AT, Solomon BJ, Chiari R, Riely GJ, Besse B, Soo RA, Kao S, Lin CC, Bauer TM, Clancy JS, Thurm H, Martini JF, Peltz G, Abbattista A, Li S, Ou SI. Shaw AT, et al. Lancet Oncol. 2019 Dec;20(12):1691-1701. doi: 10.1016/S1470-2045(19)30655-2. Epub 2019 Oct 25. Lancet Oncol. 2019. PMID: 31669155 Clinical Trial.
The estimated median duration of follow-up for response was 21.1 months (IQR 15.2-30.3). 13 (62%; 95% CI 38-82) of 21 TKI-naive patients and 14 (35%; 21-52) of 40 patients previously treated with crizotinib as their only TKI had an objective response. Intracranial response …
The estimated median duration of follow-up for response was 21.1 months (IQR 15.2-30.3). 13 (62%; 95% CI 38-82) of 21 TKI-naive patie …
Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study.
Muscaritoli M, Lucia S, Farcomeni A, Lorusso V, Saracino V, Barone C, Plastino F, Gori S, Magarotto R, Carteni G, Chiurazzi B, Pavese I, Marchetti L, Zagonel V, Bergo E, Tonini G, Imperatori M, Iacono C, Maiorana L, Pinto C, Rubino D, Cavanna L, Di Cicilia R, Gamucci T, Quadrini S, Palazzo S, Minardi S, Merlano M, Colucci G, Marchetti P; PreMiO Study Group. Muscaritoli M, et al. Oncotarget. 2017 Aug 10;8(45):79884-79896. doi: 10.18632/oncotarget.20168. eCollection 2017 Oct 3. Oncotarget. 2017. PMID: 29108370 Free PMC article.
For inclusion, adult patients (>18 years) had a solid tumor diagnosis, were treatment-naive, and had a life expectancy >3 months. Malnutrition was identified by the Mini Nutritional Assessment (MNA), appetite status with a visual analog scale (VAS), and appetite loss …
For inclusion, adult patients (>18 years) had a solid tumor diagnosis, were treatment-naive, and had a life expectancy >3 month …
Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease.
Danese S, Sandborn WJ, Colombel JF, Vermeire S, Glover SC, Rimola J, Siegelman J, Jones S, Bornstein JD, Feagan BG. Danese S, et al. Gastroenterology. 2019 Oct;157(4):1007-1018.e7. doi: 10.1053/j.gastro.2019.06.038. Epub 2019 Jul 4. Gastroenterology. 2019. PMID: 31279871 Free article. Clinical Trial.
RESULTS: At week 26, 11.9% of patients were in endoscopic remission (95% confidence interval [CI] 6.3-9.8); at week 52, 17.9% of the patients were in endoscopic remission (95% CI 8.9-30.4). Higher proportions of patients naive to TNF antagonists achieved endoscopic remissi …
RESULTS: At week 26, 11.9% of patients were in endoscopic remission (95% confidence interval [CI] 6.3-9.8); at week 52, 17.9% of the patient …
589 results